The addition of atezolizumab to standard neoadjuvant chemotherapy followed by adjuvant atezolizumab did not significantly improve event-free survival (EFS) in patients with stages II-III triple ...

In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, 1 response awaiting ...